

Disclosure Report and Methodology Note

Organon Sweden 2025 Disclosure Report

Date of publication: 13-May-2026

	Full name <i>(article 2)</i>	HCPs: City of Principal Practice HCOs: city of practice (registered address) <i>(article 9)</i>	Country of principal practice <i>(article 1)</i>	Principal practice address (e.g. clinic/office/healthcare unit/department) <i>(article 9)</i>	Unique identifier - OPTIONAL <i>(article 9)</i>	Donations to HCOs (article 9)	Contribution to costs of events (article 9)			Fee for service and consultancy (article 9)		TOTAL OPTIONAL
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an event	Registration fees	Travel and accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel and accommodation	
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
HCPs	BRYNHILDSEN, Jan	ÖREBRO	SE	Universitetssjukhuset Örebro-Obstetrik och gynekologi USÖ, Södra Grev Rosengatan		N/A	N/A	N/A	N/A	60 000,00	8 971,79	68 971,79
	CIDH, Åsa	TENHULT	SE	Migränhjälpen Norden AB, Norra Vägen 1		N/A	N/A	N/A	N/A	13 000,00		13 000,00
	ENVALL, Niklas	DANDERYD	SE	KI Nord-KIDS Inst för klin vetenskaper Danderyd, Entrévägen 2		N/A	N/A	N/A	N/A	20 000,00	3 525,56	23 525,56
	GEMZELL DANIELSSON, Kristina	SOLNA	SE	Karolinska Univ Sjh Solna- Tema Kvinnohälsa och Hälsoprofessioner, Eugeniavägen 23		N/A	N/A	N/A	N/A	2 998,20		2 998,20
	KOPP KALLNER, Helena	DANDERYD	SE	Danderyds sjukhus- Kvinnosjukvård och forlossning, Entrévägen 2		N/A	N/A	N/A	N/A	3 402,60		3 402,60
OTHER, not included above - where information cannot be disclosed on an individual basis with regard to the General Data Protection Regulation												
Aggregate amount attributable to transfers of value to such Recipients - article 10						N/A	N/A	N/A	N/A			0,00
Number of Recipients						N/A	N/A	N/A	N/A			0
% of total number of recipients of individual HCPs						N/A	N/A	N/A	N/A			N/A
INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
HCOs	Coreful AB	MÖLNDAL	SE	Bigatan 18			N/A	N/A	12 500,00			12 500,00
	FSUM	STOCKHOLM	SE	Sankt Paulsgatan 19		20 395,25	N/A	N/A				20 395,25
	HuvudvärksAkademien AB	LUND	SE	Winstrupsgatan 1		38 850,00	N/A	N/A				38 850,00
	Källmet AB	TÄBY	SE	Parkvägen 51			N/A	N/A	20 000,00			20 000,00
	Oliven Invest AB	SOLLENTUNA	SE	Hedvigsdalsvägen 18C			N/A	N/A	12 500,00			12 500,00
	Preventi AB	BROMMA	SE	Grangårdevägen 18			N/A	N/A	25 000,00			25 000,00
	Svensk Förening Obstetrik och Gynekologi-NFOG Nordic Fed of Soc Obstetrik and Gyn	STOCKHOLM	SE	Klara Östra kyrkogata 10		25 000,00	N/A	N/A				25 000,00
	Svenska Hjärtförbundet	UMEÅ	SE	Daniel Naezéns väg		17 900,00	N/A	N/A				17 900,00
	Svenska Läkaresällskapet-Svenska Kardiologföreningen	STOCKHOLM	SE	Klara Östra kyrkogata 10		163 200,00	N/A	N/A				163 200,00
	Svenska Läkaresällskapet-Svenska Neurologföreningen	LINKÖPING	SE	Ånestadsgatan 25 D		60 000,00	N/A	N/A				60 000,00
Svenska Neurologföreningen-Svenska Huvudvärksällskapet	VÄRNAMO	SE	Migränkliniken		148 833,60	N/A	N/A				148 833,60	
OTHER, not included above - where information cannot be disclosed per HCO for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients - article 10						N/A	N/A	N/A	N/A			0,00

Organon Sweden 2025 Disclosure Report

Date of publication: 13-May-2026

	Full name <i>(article 2)</i>	HCPs: City of Principal Practice HCOs: city of practice (registered address) <i>(article 9)</i>	Country of principal practice <i>(article 1)</i>	Principal practice address (e.g. clinic/office/ healthcare unit/department) <i>(article 9)</i>	Unique identifier - OPTIONAL <i>(article 9)</i>	Donations to HCOs (article 9)	Contribution to costs of events (article 9)			Fee for service and consultancy (article 9)			TOTAL OPTIONAL
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an event	Registration fees	Travel and accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel and accomodation		
	Number of Recipients					N/A	N/A	N/A	N/A				0
	% of total number of recipients of individual HCOs - article 10					N/A	N/A	N/A	N/A				N/A
R&D	AGGREGATE DISCLOSURE												
	Transfers of value re Research & Development (as defined) (article 12 and article 1)												0.00

Organon Sweden: Methodological Note for HCP/HCO Disclosure 2025

Contents

Organon Sweden: Methodological Note for HCP/HCO Disclosure 2025.....	1
Organon Sweden – Methodological Note.....	2
Introduction.....	2
1. Definitions.....	2
1.1 Recipients.....	2
1.2 Kind of ToVs.....	2
2. Disclosure’s Scope.....	3
2.1 Products concerned.....	3
2.2 Company concerned.....	3
2.4 ToVs date.....	3
2.5 Direct ToVs.....	4
2.6 Indirect ToVs.....	4
2.7 Non-monetary ToVs.....	4
2.8 ToVs in case of partial attendances or cancellation and refund.....	4
2.9 Cross-border activities.....	4
2.10 R&D.....	4
2.11 Voluntary disclosure.....	4
3. Specific considerations.....	4
3.1 Country unique identifier.....	4
3.2 Self-incorporated HCP.....	5
3.3 Multi-year agreements.....	5
4. Data protection legal basis.....	5
4.1 Consent collection.....	5
4.2 Handling of withdrawn consent.....	5
4.3 Partial consent.....	5
5. Form of disclosure.....	5
5.1 Date of publication.....	5
5.2 Disclosure platform.....	6
5.3 Disclosure language.....	6
6. Disclosure financial data.....	6
6.1 Currency.....	6
6.2 VAT included or excluded.....	6
6.3 Calculation rules.....	6
7. Additional Information.....	6

Organon Sweden: Methodological Note for HCP/HCO Disclosure 2025

Version: Last updated 13 May 2026

Country: Sweden

Data year: 2025

Year of publication: 2026

Organon Sweden – Methodological Note

Introduction

This Methodology Statement defines the relevant types of transfers to be disclosed, which transfers are excluded, and other relevant information to assist the reader understand how Organon collected, organized and reported the disclosed data in Sweden. It follows the mandatory EFPIA standardised structure to support clarity and comparability of disclosure information.

1. Definitions

1.1 Recipients

Healthcare Professional (HCP): Any natural person that is a member of the medical, dental, pharmacy or nursing professions, or any other person who, as part of their professional activities, may prescribe, purchase, supply or administer a medicinal product, and whose primary practice or principal professional address is in Sweden. This includes any official or employee of a governmental agency or other organisation that may prescribe, purchase, supply or administer medicinal products.

Deceased/retired recipients: Where a ToV was made prior to death or retirement, it is disclosed in the relevant data year.

Healthcare Organisation (HCO): Any healthcare, medical or scientific organisation such as a hospital, clinic, foundation, university, other teaching institution or learned society (excluding patient organisations), through which one or more HCPs provide services and whose place of incorporation is in Sweden.

1.2 Kind of ToVs

Organon discloses the following kinds of ToVs:

HCOs:

- Donations and Grants for supporting healthcare, scientific research or education (no benefit in return).

- Contributions to costs related to events (e.g., sponsorship agreements, booth/stand hire, satellite symposia).
- Fees for services and consultancy (and related expenses).

HCPs:

- Contributions to costs related to events (registration fees; travel and accommodation).
- Fees for service and consultancy (e.g., speaking, advisory services, medical writing, data analysis, development of educational materials, market research when the identity is known to Organon).

Research & Development (R&D):

ToVs related to non-clinical studies, clinical trials and prospective non-interventional studies that involve collection of patient data.

2. Disclosure's Scope

2.1 Products concerned

This disclosure covers Transfers of Value related to prescription-only medicinal products. Transfers solely related to over-the-counter medicines or medical devices are not included.

2.2 Company concerned

This disclosure covers all relevant ToVs to recipients in Sweden associated with the Organon group regardless of which Organon entity contracted with or paid a recipient.

2.3 Excluded ToVs

The following ToVs are excluded from disclosure:

- ToVs solely related to over-the-counter medicines.
- Ordinary course purchases and sales of medicines (e.g., between Organon and a pharmacy).
- Medical samples, investigational compounds and biological samples for study.
- Informational or educational materials and items of medical utility.
- ToVs to patient organisations (disclosed separately under relevant requirements).
- Meals and drinks.

2.4 ToVs date

Direct ToVs are disclosed based on the date Organon paid the ToV. E.g. if the payment occurred within the reporting period 1st January 2025 to 31st December 2025, the TOV would be disclosed in the 2025 report.

Indirect ToVs concerning travel and accommodation are disclosed based on the date the event took place. E.g. if the travelling occurred within the reporting period 1st January 2025 to 31st December 2025, the iTOV would be disclosed in the 2025 report.

2.5 Direct ToVs

Direct ToVs include, for example:

- Fees for service and consultancy paid, and related expenses, paid directly to HCPs or HCOs.
- Donations and Grants paid directly to HCOs.
- Sponsorships or contributions to costs of events paid to HCOs.

2.6 Indirect ToVs

Indirect ToVs include, for example:

- Travel and accommodation arranged or reimbursed through intermediaries for HCPs.
- Sponsorships or contributions to costs of events paid to third parties on behalf of HCOs.

2.7 Non-monetary ToVs

Where non-monetary ToVs are provided (e.g., in-kind support or staff time within collaborative projects), these are valued at the actual cost to Organon using available internal records and are disclosed within the relevant category.

2.8 ToVs in case of partial attendances or cancellation and refund

ToVs are reported on the basis of what Organon paid, not what the recipient ultimately received. Accordingly, in cases of partial attendance, the full amount paid by Organon is disclosed. Where a HCP cancels and no cost is incurred by Organon, no ToV is disclosed.

2.9 Cross-border activities

All ToVs to Sweden recipients are disclosed in the Sweden, irrespective of which Organon entity contracted with, organised or paid for the activity.

2.10 R&D

R&D ToVs include those related to non-clinical studies (as per OECD Principles on Good Laboratory Practice), clinical trials (as per Directive 2001/20/EC), and prospective non-interventional studies involving data collection from, or on behalf of, HCPs/HCOs.

2.11 Voluntary disclosure

Not applicable.

3. Specific considerations

3.1 Country unique identifier

Organon uses internal commercial identifiers to uniquely identify recipients within our systems.

3.2 Self-incorporated HCP

Publication of value transfers is done on the name of the formal recipient. Thus, a fee paid to a legal entity such as an entity owned by an HCP will be recorded on the company's name (which constitutes an HCO) and not on the individual's name because it is the entity that is the recipient of the value transfer.

3.3 Multi-year agreements

For multi-year agreements, Organon discloses the value in the year in which the ToV is made (i.e., when the cost is incurred/paid), with amounts reported for each calendar year accordingly.

4. Data protection legal basis

4.1 Consent collection

According to the European General Data Protection Regulation (GDPR), Organon Sweden shall be able to demonstrate that consent to the processing of personal data has been collected from individuals (HCP) and for HCOs, which are individual HCPs for publishing personal information. Organon has done its utmost to collect the consent of the recipients of value transfers concerned. Organon has used independent consent that covers all activities. For HCP or Individual firm (HCO) where Organon has not obtained consent, the sum of these value transfers will be reported in aggregate form together with the total number and % share of HCPs that have not consented.

4.2 Handling of withdrawn consent

A recipient of value transfer has the right to withdraw his or her consent at any time. Staff can contact Organon at the following e-mail address: PrivacyTeam@organon.com . If this occurs before Organon has published the value transfers, the individual or individual firm will be reported in aggregated form where the name of the individual or individual firm is not mentioned. If the consent is withdrawn after publication, the already published information on the recipient's name, as well as the type and size of value transfer will be removed from individual reporting and instead added to the aggregated statement.

4.3 Partial consent.

If an HCP only agrees to the publication of fair parts of its received value transfer (which is not in the interests of Organon or EFPIA), Organon will report all value transfers to that recipient in aggregated form where the name of the individual or individual firm is not mentioned. A publication of only fair parts of a value transfer would be misleading regarding the type and extent of interaction between Organon and the HCP.

5. Form of disclosure

5.1 Date of publication

Latest last working day of June each year but preferably last working day of May, as instructed by LIF (Pharma association Sweden).

5.2 Disclosure platform

Disclosure is made via the Organon Sweden website.

5.3 Disclosure language

English

6. Disclosure financial data

6.1 Currency

SEK. Where costs are incurred in other currencies, values are converted using the exchange rate applicable on the date the cost is incurred/posting date within Organon's finance systems.

6.2 VAT included or excluded

Indirect ToVs (e.g., travel and accommodation arranged on behalf of, or reimbursed to, HCPs) include VAT. Direct payment ToVs exclude VAT (Organon recovers VAT where applicable).

6.3 Calculation rules

Disclosed ToVs reflect the actual cost paid by Organon. In-kind/non-monetary ToVs (if any) are measured at Organon's cost. Refunds and credit notes are netted in the period they post, aligned to the ToV recognition rules described in Section 2.4.

7. Additional Information

For all queries contact: privacyteam@organon.com.